Previous Close | 0.1024 |
Open | 0.1047 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.1047 - 0.1047 |
52 Week Range | 0.0808 - 0.3680 |
Volume | |
Avg. Volume | 5,926 |
Market Cap | 17.25M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4 The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Comp
Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-g
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference to be held on April 27-28, 2022. Individual investors, institutional investors, advisors, and analysts are invited to attend this tw